Targeting of sonic hedgehog-GLI signaling: A potential strategy to improve therapy for mantle cell lymphoma

Molecular Cancer Therapeutics

Volumn 7, Issue 6, 2008, Pages 1450-1460

  Hegde, Ganapati V ^a   Munger, Corey M ^a   Emanuel, Katy ^a,c   Joshi, Avadhut D ^a   Greiner, Timothy C ^b   Weisenburger, Dennis D ^b   Vose, Julie M ^b   Joshi, Shantaram S ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NEBRASKA WESLEYAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLOPAMINE; DOXORUBICIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; CYCLIN D1; GLI1 PROTEIN, HUMAN; PROTEIN BCL 2; TRANSCRIPTION FACTOR;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DOWN-REGULATION; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; LYMPHOMA, MANTLE-CELL; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 49849084682     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2118     Document Type: Article

References (41)

1. Bertoni F, Rinaldi A, Zucca E, Cavalli F. Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 2006;24:22-7.
2. Bertoni F, Zucca E, Cavalli F. Mantle cell lymphoma. Curr Opin Hematol 2004;11:411-8.
3. Zelenetz AD. Mantle cell lymphoma: an update on management. Ann Oncol 2006;17 Suppl 4:iv12-4.
4. O'Connor OA. Mantle cell lymphoma: identifying novel molecular targets in growth and survival pathways. Hematol Am Soc Hematol Educ Program 2007;2007:270-6.
5. Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 2003;3:903-11.
6. Bhardwaj G, Murdoch B, Wu D, et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2001;2:172-80.
7. Lowrey JA, Stewart GA, Lindey S, et al. Sonic hedgehog promotes cell cycle progression in activated peripheral CD4(+) T lymphocytes. J Immunol 2002;169:1869-75.
8. Benson RA, Lowrey JA, Lamb JR, Howie SE. The notch and sonic hedgehog signalling pathways in immunity. Mol Immunol 2004;41:715-25.
9. Sacedon R, Diez B, Nunez V, et al. Sonic hedgehog is produced by follicular dendritic cells and protects germinal center B cells from apoptosis. J Immunol 2005;174:1456-61.
10. Kasper M, Regl G, Frischauf AM, Aberger F. GLI transcription factors: mediators of oncogenic hedgehog signalling. Eur J Cancer 2006;42:437-45.
11. Rubin LL, de Sauvage FJ. Targeting the hedgehog pathway in cancer. Nat Rev Drug Discov 2006;5:1026-33.
12. Barnes EA, Heidtman KJ, Donoghue DJ. Constitutive activation of the shh-ptc1 pathway by a patched1 mutation identified in BCC. Oncogene 2005;24:902-15.
13. Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005;152:43-51.
14. Ruiz i Altaba A, Sanchez P, Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2002;2:361-72.
15. Cengel KA. Targeting sonic hedgehog: a new way to mow down pancreatic cancer? Cancer Biol Ther 2004;3:165-6.
16. Katano M. Hedgehog signaling pathway as a therapeutic target in breast cancer. Cancer Lett 2005;227:99-104.
17. Romer J, Curran T. Targeting medulloblastoma: small-molecule inhibitors of the sonic hedgehog pathway as potential cancer therapeutics. Cancer Res 2005;65:4975-8.
18. Pazzaglia S, Tanori M, Mancuso M, et al. Linking DNA damage to medulloblastoma tumorigenesis in patched heterozygous knockout mice. Oncogene 2006;25:1165-73.
19. Dierks C, Grbic J, Zirlik K, et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007;13:944-51.
20. Lindemann RK. Stroma-initiated hedgehog signaling takes center stage in B-cell lymphoma. Cancer Res 2008;68:961-4.
21. Tucker CA, Bebb G, Klasa RJ, et al. Four human t(11;14)(q13;q32)- containing cell lines having classic and variant features of mantle cell lymphoma. Leuk Res 2006;30:449-57.
22. Amin HM, McDonnell TJ, Medeiros LJ, et al. Characterization of4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 2003;127:424-31.
23. Wang P, Pavletic ZS, Joshi SS. Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation. Leuk Lymphoma 2002;43:1827-35.
24. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 2000;6:4950-6.
25. Mohammad RM, Al-Katib A, Aboukameel A, Doerge DR, Sarkar F, Kucuk O. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther 2003;2:1361-8.
26. Kayed H, Kleeff J, Osman T, Keleg S, Buchler MW, Friess H. Hedgehog signaling in the normal and diseased pancreas. Pancreas 2006;32:119-29.
27. Incardona JP, Gaffield W, Kapur RP, Roelink H. The teratogenic veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. Development 1998;125:3553-62.
28. Sanchez P, Hernandez AM, Stecca B, et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A 2004;101:12561-6.
29. Kim Y, Yoon JW, Xiao X, Dean NM, Monia BP, Marcusson EG. Selective down-regulation of glioma-ass ociated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res 2007;67:3583-93.
30. Chen X, Horiuchi A, Kikuchi N, et al. Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: its inhibition leads to growth suppression and apoptosis. Cancer Sci 2007;98:68-76.
31. Sims-Mourtada J, Izzo JG, Apisarnthanarax S, et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 2006;12:6565-72.
32. Rizzatti EG, Falcao RP, Panepucci RA, et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFβ signalling pathways. Br J Haematol 2005;130:516-26.
33. Munoz O, Fend F, de Beaumont R, Husson H, Astier A, Freedman AS. TGFβ-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation. Leukemia 2004;18:2015-25.
34. Dennler S, Andre J, Alexaki I, et al. Induction of sonic hedgehog mediators by transforming growth factor-β: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res 2007;67:6981-6.
35. van de Donk NW, Bloem AC, van der Spek E, Lokhorst HM. New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway. Curr Pharm Des 2006;12:327-40.
36. Bigelow RL, Chari NS, Unden AB, et al. Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J Biol Chem 2004;279:1197-205.
37. Regl G, Kasper M, Schnidar H, et al. Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. Cancer Res 2004;64:7724-31.
38. Oliver TG, Grasfeder LL, Carroll AL, et al. Transcriptional profiling of the sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci U S A 2003;100:7331-6.
39. Lobjois V, Benazeraf B, Bertrand N, Medevielle F, Pituello F. Specific regulation of cyclins D1 and D2 by FGF and shh signaling coordinates cell cycle progression, patterning, and differentiation during early steps of spinal cord development. Dev Biol 2004;273:195-209.
40. Kenney AM, Cole MD, Rowitch DH. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 2003;130:15-28.
41. O'Connor OA, Smith EA, Toner LE, et al. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res 2006;12:2902-11.